Chronic Rejection Driven by Complement-Mediated Microvascular Damage II
About this episode
Creative Biolabs introduces topics from functional and molecular descriptions of complement targets to development of complement-directed inhibitors and puts them in a podcast column for interested researchers.
Get every episode summarized
Each time The antibody-based pharmaceuticals resource library’s Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The antibody-based pharmaceuticals resource library’s Podcast
Webinar: Modeling T cell dysfunction in tumor microenvironments
The antibody-based pharmaceuticals resource library’s Podcast
The Future of Targeted Drug Delivery – Multimodal Imaging and Smart Nanocarriers
The antibody-based pharmaceuticals resource library’s Podcast
Sound Waves for Drug Delivery – Microbubbles, Sonoporation, and Photoacoustics
The antibody-based pharmaceuticals resource library’s Podcast
Nuclear Medicine – The Most Sensitive Way to Track Drug Delivery
The antibody-based pharmaceuticals resource library’s Podcast